Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | TDP2 | O95551 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | NSD2 | O96028 | 3/20 | 0.68 |
| ▸ | THRB | P10828 | 3/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.68 |
| ▸ | GALK1 | P51570 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | APAF1 | O14727 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808995 | 0.89 | MAPT (0.55) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL7599207 | 0.74 | BACE1 (0.47) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4183347 | 0.72 | MAPT (0.71) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4196714 | 0.70 | SMN1; SMN2 (0.67) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL7772483 | 0.69 | LMNA (0.70) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL15315053 | 0.69 | MAPT (0.54) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL10399533 | 0.69 | MAPT (0.53) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL6003260 | 0.68 | MAPT (0.57) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4190009 | 0.68 | MAPT (0.49) | LMNAMAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL29697829 | 0.68 | DHODH (0.42) | LMNAMAPTHTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036441-A1 | Indole Derivatives With Antitumor Activity | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1835908-A2 | INDOLE DERIVATIVES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066923-A2 | INDOLE DERIVATIVES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036441-A1 | Indole Derivatives With Antitumor Activity | IDO1, IDO2, INMT | LMNA 2106/4885MAPT 2732/4885HTT 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.